Connect with us

Press Release

Why will Trump win the 2020 election?

Published

on

When people think, God laughs. Trump will definitely win this election. No reason is needed, just believing. In order to avoid being labelled as a god-stick, I will talk about Eastern Zen Buddhism. When Master Bodhidharma taught the Dharma, he said that “no words are directed at people’s hearts”, pointing out that truth cannot be expressed in words, and what is expressed in words is not truth. The Diamond Sutra Buddha Shakyamuni also stated that the Buddha has never taught the real Dharma, and everything I say is not the righteous Dharma. Lao Tzu’s Tao Te Ching preaches, Tao can be very Tao, Tao is simple. Also said the unspeakable truth.

Let’s talk about the amazing experimental results of modern biology and neurology. After rigorous scientific experiments, experimental experts have discovered that the time for humans to act is before the thinking and decisions of the human brain. What does this mean? That is to say, before your brain makes a decision, your nerves command your body to act before your thinking and decision-making, but the time is so short that you can’t even notice it. Therefore, the destiny of human beings is predestined, and our brain’s thinking is only an explanation based on the results that we can understand and believe in our own behavior. In other words, we mistakenly believe that our destiny is the result of our own thinking and choices, not determined by karma and the Creator.

Therefore, I said that Trump will definitely win the 2020 election. It is a script written by God long ago. We just believe that there is no need to worry and worry. Wu Chengen, the author of Journey to the West, has a metaphor at the end of the book, that is, the Buddha recites in Tang Seng and his apprentices are not far away, and the sincerity of seeking the scriptures after hardships is commendable. At the beginning, the Tang Seng was given the Lingshan Supreme Treasure Without Words scripture, but Tang Seng discovered halfway through Later, he returned to the false scriptures, which was supposed to be a mockery of him. Finally, the Buddha lamented the dullness of the sentient beings in Nanchan Tribe, and gave Tang Seng the scriptures with words that he believed were true scriptures. As the saying goes, there must be chaos. As time goes by, the chaos of the age of human nature is degenerate, and this is the root of the chaos.

The above text is just as everyone is worried about Trump. Now, let’s make a joke with everyone and relax. Next, we will use the habit of giving reasons to believe and talk about why Trump will win the 2020 election.

First of all, in the 2020 election, Trump and Biden have both said that they won? So, is the truth important or Trump’s win?

It is more important than Trump’s win. If we think that as long as Trump can win us regardless of the truth, then Trump is just like Biden by all means to win. We are not worthy to support Trump. Therefore, we first believe that the truth is that Trump is the president elected by most Americans, and Biden’s subsequent overtake is the result of cheating.

The fact is also that all the states where Biden later overtook the bizarre number of votes than registered voters. Suddenly, there was no reason to stop counting votes. After a few hours, Biden was in a rocket-like lead; there were no more than 100,000 votes in the midnight ghost. Exceptions are Biden; countless people who have been dead for many years are voting; many voters are shown to be over 120 or even 170 years old; thousands of votes cast by Trump are found to be counted as Biden; democracy Party states violated regulations to prohibit Republican vote-taking inspectors from jointly scrutinizing votes; some states use the voting system produced by Pelosi’s companies, whether or not Trump’s votes are recorded as voting for Biden, and so on. Then according to many Statehouse synchronized elections member of Republican senators are leading Democrat victory over a dozen points, while in the same region Trump has lost Biden to analyze the phenomenon, in addition to the Democratic ballot fraud cheating In addition, the only explanation is that the local voters are schizophrenic. They voted for Republican congressmen, but they magically voted for the Democratic president.

Therefore, there are no waves without wind, and there must be demons in the abnormal. We have reason to believe the truth is that Trump significantly ahead of Biden, and actually 11 Yue 3 statutory election day has been fantastic, and then to begin the Democrats no bottom line in several key states, no scruples, unprincipled vote cheating Falsification has led to the current situation where Biden has overtaken and is almost winning, and this kind of vote falsification is a premeditated, well-prepared and widely organized behavior.

Then the current crisis so acute Biden and White House seems one step, one-sided mainstream media social software to Biden’s case, Trump win it? Yes, Trump will definitely win, he will enter the White House in 2021 , lead the United States, lead the world, and complete his unfinished business, and the four-year Trump term in the second term will be more exciting and more exciting than the first term. People are excited because Trump never disappoints his supporters and always gives more than expected. In the 2020 U.S. election, Trump will win and must win, because if Trump is cheated by the Biden Democratic Party this time, there will never be a future. This is the final battle. If we cannot defend our votes this time, there will be no votes that truly represent our will in the future.

Talk about three reasons Trump must win:

The first administrative judicial system to resolve disputes peacefully is beneficial to Trump

A major feature of democratic countries is that there are disputes that can be resolved peacefully instead of violence by relying on a trustworthy system. The separation of powers in the United States: Judiciary, Congress, and Administration. The number of Supreme Court justices is the absolute advantage of the Republican Party. Trump counts as one point; Congress Trump controls the Senate majority party as 0.5 points; Biden controls the House majority party as 0.5 points; the administration is controlled by Trump’s White House team and counts one point; if necessary If the mainstream media is considered the fourth right, then Biden is one point; the comparison is that Trump 2.5 points to Biden 1.5 points, and Trump is better than Biden in resolving disputes between the two sides of a normal procedure and peaceful gentleman.

The second people have the awareness and ability to defend the elected President Trump with arms

Trump’s Republican Party has always supported the American people’s right to own guns, while the Democrats are the opposite. Because Gong Huo Party Performed constitutional rationale idea is that the American people have the right to armed overthrow of tyranny, so people have the right gun. As the saying goes, there is a lingering fragrance in the hands of roses. Armed people also have the ability to defend their elected president. Most of the supporters of the Republican Party are voters with gun ideas and qualifications. Various militia organizations and firearms associations will hold weapons to deter all conspiracies that dare to use improper means to overthrow the elected president. In the face of such an armed people, any conspirator must be cautious when doing evil. The key is that the only possible participation of the armed forces police force is Trump’s staunch supporter, thanks to the Biden Democratic Party for supporting Antifa and other ultra-left organizations to mess up the United States to fish in troubled waters and long-term suppression of the police system. US military owned by the state is not involved in internal party strife, that decorum situation under conditions, Trump force values can be easily rolled Biden Democrats. To put it straightforwardly, Biden controls the American moneybags (Wall Street and big capitalists) and pens (mainstream media and high-tech companies), but Trump controls the American knives (police and armed people). If the Democratic Party can’t resolve the election disputes peacefully by playing a rogue, the knife is much easier to use than a purse and a pen.

Third, Trump’s Taoists help others to help themselves

One of the most critical factors for Trump to win is that Trump deserves this victory! He is a tough fighter who will never give up. In the face of even more sinister conspiracies and powerful enemies, as long as you don’t give up, someone will fight with you until you succeed. Trump has proven to us that he is a warrior who is more and more courageous until victory. The Biden Democrats are accustomed to conspiracy, but this time the bully found the wrong opponent and kicked it on the steel plate. The U.S. Supreme Court has intervened in the vote fraud case at Trump’s request; the U.S. Senate and the Republican Party have announced that they will stand with Trump under any circumstances; voters in 50 U.S. states have begun to take to the streets to support Trump and protect their President recapture the votes are represented by Democrat Joe Biden; large main American religious teachings explicitly called on all those who believe in God the United States (population accounted for 60% ) strongly supports Trump, is standing on the side of God against the sub-plot to reshape the world of darkness; There are also the jealous relatives of Trump’s first family from his wife to his son, daughter, and son-in-law, who have always given Trump spiritual and deed support that others cannot give.

The most important thing is in God and with Donald Trump, Trump with God and in the upper Di and with Donald Trump in. Many friends think that God’s blessing is just a blessing, but I think this is the fundamental factor that Trump must win, because apart from this, the rest are for people to understand and talk about, and this is the real reason. Friends, we ask ourselves why we support Trump? Is it for the benefit of policy or to make more money for yourself, or is it because you hate Biden? If it is not, it is because we want to see justice done, fairness upheld, truth can be announced, and freedom protected. We believe that Trump represents light and hope, and we support the production and generalization so that our children can live in a beautiful, fair and orderly world in the future, so please believe that our support for Trump is a blessed power. It comes from the original love of all things. So Trump will surely get God’s favor.

Why is Trump sure to win, because God is with Trump, the son of light, and all those who support Trump because of love!

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China

Published

on

SHENZHEN, CHINA – On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China.

 

Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points

Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, providing immediate protection before the establishment of full protection by active rabies vaccination, and building a critical line of defense against viral infection.

 

The Product is currently the passive immunization product with the smallest dose for rabies (0.05 mg/kg); compared with human rabies immune globulin (“HRIG”), it requires less injection volume and easier administration, which can effectively reduce pain and improve compliance for patient. Manufactured using recombinant technology, the Product is non-plasma-derived and carries no risk of blood-borne infections. It can be manufactured at scale through standardized and stable processes, with controllable production costs, while offering a single active ingredient, consistent quality and minimal batch-to-batch variability. These advantages open up new possibilities for improving the safety, standardized supply and patient accessibility of rabies passive immunization products, with the potential to further increase market penetration.

 

Initial Prescriptions Issued Within About Two Months After Approval, Academic-Driven Commercialization Platform Accelerating Value Realization

Silevimig Injection was approved for marketing in China in June 2026. Following the approval, CMS worked closely with its partner Genrix Bio to advance critical workstreams including drug supply, market access and academic promotion, while integrating expert networks and market resources. The inital prescriptions were issued in China within approximately two months, accelerating the translation of innovation outcomes into a clinically accessible new treatment option.

 

Currently, CMS has nine commercialized innovative drugs that are progressively achieving large-scale clinical application across China, accelerating the realization of the clinical value of each quality medicine. Going forward, CMS will remain focused on clinical unmet needs and continue to build a differentiated innovative product portfolio through a dual-track system of in-house R&D and collaborative R&D, accelerating accessibility of quality innovative drugs and taking concrete action to safeguard patients’ lives and health.

 

About Rabies

Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage [1].

 

According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure, patients with confirmed Category II exposure involving severe immunodeficiency, and patients with Category II exposure involving wounds to the head or face while the health status of the offending animal cannot be determined should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high price, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary passive immunization option in China is HRIG. However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China.

 

More Information about Silevimig Injection

In a Phase III clinical trial in adults in China, Silevimig Injection met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China.

 

In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product.

 

About CMS

CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.

 

CMS has established an end-to-end capability loop across the full product lifecycleprecisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.

 

CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.

 

Reference:

1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P02024090652542…

2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis [J]. Chinese Journal of Preventive Medicine, 2019, 53(7): 668679. DOI: 10.3760/cma.j.issn.0253-9624.2019.07.004

3. Chinese Center for Disease Control and Prevention. National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Ekiden Launches Canton Network’s First Order Book-Based Derivatives Exchange

Published

on

Lisbon, Portugal, September 9th, 2026, FinanceWire

Ekiden, the first order book-based derivatives exchange, brings institutional-grade execution, private trading workflows, and on-chain settlement to the Canton ecosystem. 

The launch adds a professional execution layer to Canton’s growing financial ecosystem, enabling market participants to trade and settle derivatives on-chain using infrastructure designed around the requirements of institutional markets. 

Ekiden is built for professional trading firms, market makers, funds, banks, and institutional trading desks that require execution workflows closer to traditional capital markets than to retail-focused decentralized finance venues. 

The platform combines a central limit order book, or CLOB, with request-for-quote execution, PropAMM integration, a professional trading terminal, and API connectivity for market makers, algorithmic trading platforms, aggregators, exchanges, and funds. 

Ekiden also provides a streamlined entry point into the Canton ecosystem, allowing professional market participants to onboard, connect through its API, and begin trading without having to build their own Canton-native infrastructure.

Canton Network provides a privacy-enabled and interoperable environment for regulated financial markets, allowing institutions to coordinate transactions without making commercially sensitive information publicly visible. Ekiden extends that environment into derivatives trading by bringing execution, liquidity, and settlement together within a single venue. 

“Ekiden’s mainnet is a notable addition to Canton’s application layer, bringing order book execution, privacy, and settlement into a single venue designed for professional trading,” said Viv Diwakar, Head of the Canton Foundation. “Launches like this act as a catalyst as the network broadens its offerings in on-chain derivatives, and we look forward to seeing a range of venues and participants contribute to that growth over time.”

According to a 2026 Coinbase and EY survey, 73% of institutional decision-makers plan to increase their digital asset allocations. Supporting this growth requires reliable execution, liquidity, price discovery, privacy, and infrastructure capable of handling institutional order flow.

“Tokenization alone does not create institutional markets,” said Vitali Dervoed, founder and CEO of Ekiden. “For tokenized assets to trade at scale, institutions need execution quality, liquidity, privacy, and workflows that reflect how professional trading actually works. Canton provides the institutional environment. We add the trading infrastructure layer for on-chain derivatives.” 

Existing on-chain trading venues have largely developed around retail participation, passive liquidity pools, and public execution environments. Professional trading firms have different requirements, including deterministic execution, low-latency API access, configurable privacy, and the ability to manage positions and capital movements without exposing commercially sensitive information to the wider market. 

Ekiden’s architecture is intended to address these requirements while preserving the operational benefits of on-chain settlement. The platform allows the lifecycle of a derivatives transaction from price discovery and execution through to settlement to take place within Canton’s privacy-enabled environment. 

During its first week on the Canton testnet, Ekiden recorded 1,502 active users, more than 72,000 trades, and approximately $8.9 million in trading volume. The company is working with 11 integration partners and has integrated 12 market makers ahead of its expansion on mainnet. 

Initial liquidity is supported by market makers, including Keyrock, Kappa Lab, and Flowdesk. Ekiden plans to add further liquidity providers, onboard more institutional participants, and expand the range of derivatives available through the platform. 

In May 2026, Ekiden raised $2 million in seed financing to develop institutional-grade infrastructure for on-chain derivatives. The round included investors and strategic participants connected to GSR, Flowdesk, Pyth, Aptos, G20, DCF God, Curiosity Capital, and Keyrock. 

The mainnet launch strengthens Canton Network’s position as infrastructure for institutional digital markets by adding a dedicated venue for derivatives execution and settlement. It also broadens the range of financial activity that can take place across the network while maintaining the privacy and workflow controls required by professional market participants.

About Ekiden

Ekiden operates an institutional derivatives exchange on Canton Network, combining central limit order book and request-for-quote execution with on-chain settlement, privacy controls, and institutional custody workflows. The platform is live and open to proprietary trading firms, funds, market makers, and bank trading desks.

Get started

Onboarding information and API documentation are available at ekiden.fi

Contact

Sofia Bobrik
TechWaves PR
ceo@techwavespr.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Ekiden Launches Canton Network’s First Order Book-Based Derivatives Exchange

Published

on

Lisbon, Portugal, September 9th, 2026, FinanceWire

Ekiden, the first order book-based derivatives exchange, brings institutional-grade execution, private trading workflows, and on-chain settlement to the Canton ecosystem. 

The launch adds a professional execution layer to Canton’s growing financial ecosystem, enabling market participants to trade and settle derivatives on-chain using infrastructure designed around the requirements of institutional markets. 

Ekiden is built for professional trading firms, market makers, funds, banks, and institutional trading desks that require execution workflows closer to traditional capital markets than to retail-focused decentralized finance venues. 

The platform combines a central limit order book, or CLOB, with request-for-quote execution, PropAMM integration, a professional trading terminal, and API connectivity for market makers, algorithmic trading platforms, aggregators, exchanges, and funds. 

Ekiden also provides a streamlined entry point into the Canton ecosystem, allowing professional market participants to onboard, connect through its API, and begin trading without having to build their own Canton-native infrastructure.

Canton Network provides a privacy-enabled and interoperable environment for regulated financial markets, allowing institutions to coordinate transactions without making commercially sensitive information publicly visible. Ekiden extends that environment into derivatives trading by bringing execution, liquidity, and settlement together within a single venue. 

“Ekiden’s mainnet is a notable addition to Canton’s application layer, bringing order book execution, privacy, and settlement into a single venue designed for professional trading,” said Viv Diwakar, Head of the Canton Foundation. “Launches like this act as a catalyst as the network broadens its offerings in on-chain derivatives, and we look forward to seeing a range of venues and participants contribute to that growth over time.”

According to a 2026 Coinbase and EY survey, 73% of institutional decision-makers plan to increase their digital asset allocations. Supporting this growth requires reliable execution, liquidity, price discovery, privacy, and infrastructure capable of handling institutional order flow.

“Tokenization alone does not create institutional markets,” said Vitali Dervoed, founder and CEO of Ekiden. “For tokenized assets to trade at scale, institutions need execution quality, liquidity, privacy, and workflows that reflect how professional trading actually works. Canton provides the institutional environment. We add the trading infrastructure layer for on-chain derivatives.” 

Existing on-chain trading venues have largely developed around retail participation, passive liquidity pools, and public execution environments. Professional trading firms have different requirements, including deterministic execution, low-latency API access, configurable privacy, and the ability to manage positions and capital movements without exposing commercially sensitive information to the wider market. 

Ekiden’s architecture is intended to address these requirements while preserving the operational benefits of on-chain settlement. The platform allows the lifecycle of a derivatives transaction from price discovery and execution through to settlement to take place within Canton’s privacy-enabled environment. 

During its first week on the Canton testnet, Ekiden recorded 1,502 active users, more than 72,000 trades, and approximately $8.9 million in trading volume. The company is working with 11 integration partners and has integrated 12 market makers ahead of its expansion on mainnet. 

Initial liquidity is supported by market makers, including Keyrock, Kappa Lab, and Flowdesk. Ekiden plans to add further liquidity providers, onboard more institutional participants, and expand the range of derivatives available through the platform. 

In May 2026, Ekiden raised $2 million in seed financing to develop institutional-grade infrastructure for on-chain derivatives. The round included investors and strategic participants connected to GSR, Flowdesk, Pyth, Aptos, G20, DCF God, Curiosity Capital, and Keyrock. 

The mainnet launch strengthens Canton Network’s position as infrastructure for institutional digital markets by adding a dedicated venue for derivatives execution and settlement. It also broadens the range of financial activity that can take place across the network while maintaining the privacy and workflow controls required by professional market participants.

About Ekiden

Ekiden operates an institutional derivatives exchange on Canton Network, combining central limit order book and request-for-quote execution with on-chain settlement, privacy controls, and institutional custody workflows. The platform is live and open to proprietary trading firms, funds, market makers, and bank trading desks.

Get started

Onboarding information and API documentation are available at ekiden.fi

Contact

Sofia Bobrik
TechWaves PR
ceo@techwavespr.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST